Workbook sheet
If a GLP-1 claim is denied
A denial is a document. It should say what was denied, under what rule, and how to challenge it. If the paper or the portal message does not say those things, the first task is to get them, not to pick a new drug the same day. This sheet is an administrative sequence. It is not legal advice and not a statement that your denial was wrong. Clinical eligibility is a different question, outlined for readers on who typically qualifies. That page does not overturn a plan.
Read the reason before you appeal the wrong thing
Denials tend to fall into a few types.
The drug is excluded. The plan document says it does not pay for weight-management drugs, or does not pay for this one. An appeal that only repeats your BMI will not add a benefit the contract lacks. You can still ask the employer or the plan whether an exception process exists. You should not expect prior authorization to invent a covered category. Cash pay and manufacturer offers are the practical fork. They are on the cash-price and savings sheets.
The drug is covered only for another indication. Diabetes GLP-1 drugs are often on formulary when Wegovy or Zepbound for weight is not. That is not a hint to ask the prescriber to pretend you have diabetes. It is a hint to check whether you do have a labeled use the plan covers: type 2 diabetes, cardiovascular risk reduction where the label and the plan allow it, obstructive sleep apnea for Zepbound, or MASH where that indication is recognized. CMS’s Bridge instructions tell prescribers the opposite of disguise. If the use is one Part D covers, send it to the Part D plan. If the use is weight management and the person meets Bridge criteria, use the Bridge. Coding the visit as something it is not is not a strategy this sheet will walk through.
Prior authorization was missing or incomplete. The pharmacy rejected the claim because the form was never sent, was sent for the wrong strength, or lacked a BMI or a comorbidity the plan asked for. This is the denial most likely to move when the prescriber resubmits. Call the pharmacy and ask for the rejection code in words. Call the plan and ask what is missing. Give that list to the prescriber’s office. Do not assume the office saw the rejection.
Step therapy was not met. The plan wants a different drug tried first, or wants notes from a supervised lifestyle program. You can ask for an exception if the required drug is inappropriate, and the prescriber has to say why. You can also look at whether the required step is a drug you already took. Old records help. Memory does not always count.
Quantity or timing. A refill too soon, or a 90-day fill the plan does not allow, looks like a denial and is often a limit. Ask the pharmacy when the next fill will go through. Escalating to a new strength can look like a second fill of the same month. The new prescription may need its own authorization.
Medicare denials are two systems
If you are in Part D and the use is diabetes, sleep apnea, MASH, or cardiovascular risk reduction as CMS described it, the denial is a Part D denial. The plan has to follow its exception and appeal process. CMS has said it watches formulary practices so that plans do not push Part D-coverable uses onto the Bridge. If a plan tells you to use the Bridge for a use the provider page says belongs to Part D, ask the plan to process the Part D request, and keep the name of the person you spoke with.
If you are seeking weight-management coverage through the Medicare GLP-1 Bridge, CMS says there is no appeal. A prescriber who made an error on the form, or who has new information, may resubmit. That is different from a multi-level appeal. The clinical criteria are specific. A BMI of 32 without one of the listed conditions was not, on the page reviewed November 18, 2026, the same as a BMI of 35 or a BMI of 27 with a previous heart attack. Read the criterion you think you meet and see whether the form attested to it. The Bridge also has plan-type limits. A denial that says the plan type is ineligible will not be fixed by a higher BMI.
The $50 Bridge copay, if you are approved, is not a commercial savings card. Do not try to stack it with a NovoCare or Lilly offer that excludes government beneficiaries.
What to ask the prescriber’s office
Ask for the indication they submitted and the BMI and date on the form. Ask whether they received the plan’s question list. Ask whether a peer-to-peer review is available. Those calls are sometimes offered and sometimes not. Ask for a copy of what was sent, so you are not appealing a form you have never seen. Offices are busy. A single page from you with the plan’s missing-item list is easier to act on than a general request to “appeal everything.”
If the prescriber believes the drug is inappropriate, an appeal is the wrong tool. The right tool is understanding the clinical reason, especially if it is a contraindication you would need to tell the next clinician. Wegovy and Zepbound are contraindicated with a personal or family history of medullary thyroid carcinoma or with MEN 2. No appeal changes that.
Paths that are not appeals
Paying cash for an FDA-approved product, using a manufacturer self-pay price if you qualify, is a financial decision. It does not require the plan to have been wrong.
Switching to a different approved product that the plan does cover can be reasonable if the indication fits. It is a new prescription. It is not a generic substitution a pharmacist can make between Wegovy and Zepbound. They are different molecules.
Using a compounded product because the approved drug was denied is the decision FDA has been warning about. Compounded semaglutide and tirzepatide are not approved, are not generics, and have been tied in FDA communications to dosing errors and to marketing claims the agency has challenged. Cost is a real pressure. It does not make those warnings disappear. The oral and compounded monograph collects the FDA language. Read it before you treat a denial as a referral to a vial.
Stopping the attempt is also allowed. A denied drug you cannot afford and do not want to appeal is not a personal failure. Lifestyle treatment remains the foundation NIDDK describes, with or without a prescription. This workbook will not dress that up as an equal substitute for a drug trial’s average result. It will say that an unaffordable plan is not a plan.
A sequence that wastes less time
- Get the denial reason in writing, including the rule cited.
- Match it to one type above. Do not write a BMI appeal to an exclusion.
- If information was missing, send exactly that information.
- If the indication was wrong, ask the prescriber to correct the indication, not to embellish it.
- If the plan will not pay and the denial is final or the benefit is absent, decide among cash pay, a different covered and appropriate drug, or no drug, using the FDA warnings if a compounded product is the option in front of you.
- Keep copies. The next plan year, or the next strength, will ask again.
Telehealth or clinic matters here because the clinician who must sign the appeal has to be someone you can reach. A program that cannot produce the chart note cannot prosecute the denial. That is a practical test of the visit you already paid for.
Sources checked for this sheet
- https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-providers
- https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge/information-part-d-plans
- https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b
- https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217806s041lbl.pdf
- https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- https://glp1.here/guides/who-qualifies
- https://glp1meds.org/monographs/oral-and-compounded